Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
SPRY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.78 - $18.90
Previous CloseN/A
Volume456.05K
Average Volume (3M)2.67M
Market Cap
$984.31M
Enterprise Value$1.48B
Total Cash (Recent Filing)$275.73M
Total Debt (Recent Filing)$73.00K
Price to Earnings (P/E)174.1
Beta1.61
Next Earnings
Nov 06, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding98,826,340
10 Day Avg. Volume4,023,938
30 Day Avg. Volume2,674,283
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue15.22
Enterprise Value/Gross Profit15.55
Enterprise Value/Ebitda-58.26
Forecast
1Y Price Target
$31.25Price Target Upside232.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe analysis showed that 486 of 545 (89.2%) patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy were successfully treated with a single dose of neffy by a healthcare provider.
Financial PerformanceARS Pharma reported $12.8M in net product revenue from neffy in Type 1 allergy, demonstrating accelerating commercial momentum that validates the transformative potential of needle-free epinephrine.
Market AccessCommercial coverage reached 93% with 57% now having unrestricted access, representing a critical inflection point in market access.
Bears Say
Investor SentimentShares in ARS are trading down 15% since the company reported second-quarter earnings, despite a solid update.
Market ShareThe company has 57% commercial coverage without prior authorizations, below its initial target of reaching 80% commercial coverage.
Prescription ChallengesManagement noted that it had underappreciated how overwhelmed by patient volumes practices would be during these peak weeks, which makes doctors less willing to prescribe a new treatment as it requires additional time.
ARS Pharmaceuticals News
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $9.78 and its highest was $18.90 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
ARS Pharmaceuticals’s market cap is $984.31M.
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 49 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on Aug 13, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.458 by -$0.002.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -0.46.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 98,826,340 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.458. Following the earnings report the stock price went down -5.042%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Currently, no hedge funds are holding shares in SPRY
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.25 (232.09% Upside)
$31.25 (232.09% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 789.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.3%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.11%
12-Months-Change
Fundamentals
Return on Equity
-23.56%
Trailing 12-Months
Asset Growth
41.23%
Trailing 12-Months
Company Description
ARS Pharmaceuticals
ARS Pharmaceuticals (SPRY) is a biopharmaceutical company focused on developing novel therapeutics designed to address unmet medical needs within the field of allergy and respiratory health. The company's flagship product, Neffy, is an epinephrine nasal spray developed as a potential emergency treatment for allergic reactions, including anaphylaxis. ARS Pharmaceuticals operates within the healthcare and pharmaceuticals sector, leveraging advanced drug delivery technologies to enhance patient outcomes and provide innovative solutions for allergy management.
SPRY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant growth in revenue and prescription volume for Neffy, along with expanded global presence and commercial coverage. However, high SG&A expenses and ongoing challenges with prior authorization requirements present some concerns. The positive aspects of the call, particularly the strong revenue growth and strategic global expansion, outweigh the lowlights.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$31.25
▲(232.09% Upside)
Technical Analysis
Mesoblast
―
Immunocore Holdings
―
Edgewise Therapeutics
―
Vera Therapeutics
―
CG Oncology, Inc.
―
Ownership Overview
69.65% Insiders
10.15% Mutual Funds
0.16% Other Institutional Investors
11.49% Public Companies and
Individual Investors